An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.

Trial Details

NCT ID

NCT07598578

Phase

EARLY_PHASE1

Sponsor

Second Affiliated Hospital of Soochow University

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Azacitidine (AZA)

Locations (sample)

• Suzhou, China|31.30408,120.59538

Key Eligibility Criteria

• Age ≥18 years and ≤75 years, male or female.
• Histologically confirmed peripheral T-cell lymphoma (PTCL) by the investigating center, including: peripheral T-cell lymphoma, not otherwise specif…
• Relapsed or refractory disease after at least one prior line of systemic therapy. Relapse is defined as disease recurrence after complete response …
• Patients considered ineligible for autologous hematopoietic stem cell transplantation by the investigator, or those who refuse such treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.